Abstract:In the world plagued by the emergence of new diseases, it is essential that we accelerate the drug design process to develop new therapeutics against them. In recent years, deep learning-based methods have shown some success in ligand-based drug design. Yet, these methods face the problem of data scarcity while designing drugs against a novel target. In this work, the potential of deep learning and molecular modeling approaches was leveraged to develop a drug design pipeline, which can be useful for cases where there is limited or no availability of target-specific ligand datasets. Inhibitors of the homologues of the target protein were screened at the active site of the target protein to create an initial target-specific dataset. Transfer learning was used to learn the features of the target-specific dataset. A deep predictive model was utilized to predict the docking scores of newly designed molecules. Both these models were combined using reinforcement learning to design new chemical entities with an optimized docking score. The pipeline was validated by designing inhibitors against the human JAK2 protein, where none of the existing JAK2 inhibitors were used for training. The ability of the method to reproduce existing molecules from the validation dataset and design molecules with better binding energy demonstrates the potential of the proposed approach.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01060?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01060</a>.Supporting Information 1: details of the hyperparameters used to train various deep learning models, comparison of Janus kinase family of proteins, effectiveness of using both transfer and reinforcement learning, generated novel scaffolds, representative set of small molecules, and various physicochemical property distributions of the generative models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01060/suppl_file/ci0c01060_si_001.pdf">PDF</a>)Supporting Information 2: training and validation datasets for the case study and the dataset of generated small molecules obtained after application of all filters along with their virtual screening scores (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01060/suppl_file/ci0c01060_si_002.xls">XLS</a>)This article has not yet been cited by other publications.

Machine Learning‐Enabled Virtual Screening with Multiple Protein Structures toward the Discovery of Novel JAK3 Inhibitors: Integration of Molecular Docking, Pharmacophore, and Naïve Bayesian Classification

A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3

Integration of Multicomplex‐Based Pharmacophore Modeling and Molecular Docking in Machine Learning‐Based Virtual Screening: Toward the Discovery of Novel PI3K Inhibitors

A Case-Based Meta-Learning Algorithm Boosts the Performance of Structure-Based Virtual Screening.

Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors

Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening

Machine learning-based virtual screening for STAT3 anticancer drug target.

Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors

Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking

Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation

Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation

Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation

Discovery of novel ULK1 inhibitors through machine learning-guided virtual screening and biological evaluation

Molecular Docking and Molecular Dynamics Simulation of New Potential JAK3 Inhibitors.

Accelerating De Novo Drug Design against Novel Proteins Using Deep Learning

A Workflow Combining Machine Learning with Molecular Simulations Uncovers Potential Dual-Target Inhibitors against BTK and JAK3

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Combination of ligand‐based and structure‐based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases

Machine learning accelerates pharmacophore-based virtual screening of MAO inhibitors